Burning Rock Biotech vs NeoGenomics
BNR and NEO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNR and NEO compare
NeoGenomics grew revenue faster over the last twelve months (11.1% versus 4.6% for Burning Rock Biotech).
NeoGenomics keeps more of each dollar of sales as profit, with a net margin of −4.1% compared with −10.3% at Burning Rock Biotech.
NeoGenomics scores higher on the StockData Score (11 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNR | NEO |
|---|---|---|
| Size and price | ||
| Market cap | – | $2.0B |
| Share price | $12.74 | $15.41 |
| Change, 1 year | 12.5% | 53.9% |
| Change, 5 years | −90.8% | −58.0% |
| Beta (5Y) | 2.50 | 0.84 |
| Employees | 667 | 2,500 |
| StockData Score | ||
| Total score | 4 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 4 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.5× |
| P/B | – | 2.5× |
| FCF yield | – | −1.4% |
| Fair value | – | $19.92 |
| Margin of safety | – | 22.6% |
| Growth | ||
| Revenue growth (TTM) | 4.6% | 11.1% (better) |
| Revenue growth, 5Y average | 4.6% | 10.4% (better) |
| Profitability | ||
| Gross margin | 74.7% (better) | 44.8% |
| Operating margin | −10.2% | −6.3% (better) |
| Net margin | −10.3% | −4.1% (better) |
| FCF margin | −6.2% | −3.6% (better) |
| Return on equity | −9.9% | −3.9% (better) |
| Return on invested capital | −72.5% | −4.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.47 |
| Interest coverage | – | −15.2× |
| Current ratio | 2.99 | 3.53 (better) |
| Altman Z-score | – | 2.32 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.02% |
| Shareholder yield | – | −0.02% |
| Ownership | ||
| Held by institutions | 1.8% | 112% |
| Held by insiders | 19.0% | 1.5% |
| Insider net buying, 12 months | $11.6M (better) | −$717K |
| Short interest, % of float | – | 10.3% |
Go deeper
- BNR stock overview
- BNR income statement
- BNR valuation and score
- NEO stock overview
- NEO income statement
- NEO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.